Monday, 30 May 2016

Pharma Literati is now Amazon associate

Pharma Literati is proud to be an associate of Now all our readers can get the Amazon product links on our blogs. 

The products would be selected by the pharma literati team and would be related to the pharmacy field only. In our en-devour to serve the pharma fraternity we are happy to promote knowledge based products from

Please visit the blog to know the interesting products. 

Pharma academic research - Indian patent applications published on 6th May 2016

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.

We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at
Application No
Microemulsion based transdermal drug delivery of tea tree oil
1) Dr. Anupama Diwan
2) Dr.S. Sardana
Hindu College of Pharmacy, Sonepat, Haryana.
Novel nanoemulsion/self nanoemulsifying drug delivery system for enhanced oral bioavailability of muscle relaxant
1) Sinha, Vivek Ranjan
2) Ghai, Damanjeet
Panjab University
A novel synergistic herbal composition for enhancing immunity level in-vivo and in-vitro: its process thereof
1) Dr. Sadhana J. Rajput
2) Mrs. Reshma A. Jain
Pharmacy Department, Faculty of Technology & Engineering, The Maharaja Sayajirao University Of Baroda, Vadodara, Gujarat.
Solid lipid nanoparticles containing glipizide an effective carrier system for diabetes
1) Gupta Gajendra Jagdish Chand Beena
2) Jadhav Kisan Ramchandra
3) Pednekar Priti Padmakar Shaila
4) Kadam Vilasrao Jagannath
Not known
Topical antifungal film forming transdermal spray composition and method of preparation thereof
1) Nitin Merubhai Mori
2) Kalpesh Chhotalal Ashara
3) Navin R. Sheth
Not known
A process for the preparation of nanobiocomposite of simvastatin for enhancement of solubility and dissolution
1) Dr. S. J. Wadher
2) Yogeshkumar A. Jadhav
3) Dr. S. G. Gattani
4) Dr. T. M. Kalyankar
School of Pharmacy, Swami Ramanand Teerth Marathwada University, Nanded, Maharashtra.
A process for preparation of linezolid nanobiocomposite for sustained release
1) Dr. S. J. Wadher
2) Ms. Ankita Kamble
3) Dr. S. G. Gattani
4) Dr. T. M. Kalyankar
School of Pharmacy, Swami Ramanand Teerth Marathwada University, Nanded, Maharashtra.
A novel anti-angiogenic, anti-cancer and anti-diabetic flavonoid, Mazapotin
1) Nanjian Raaman
2) Chandrasekaran Sivaraj
University of Madras, Chennai, Tamilnadu.

Pharma academic research - Indian patent applications published on 29th April 2016

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.

We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at

Application No
Device for inducing anxiety-disorder in laboratory animals
1) Prof.(Dr.) Milind Parle
2) Dr. Isha Dhamija  
3) Neeraj Sethi
Guru Jambheshwar University of Science and Technology Campus, Hisar
Starch glutamate based fast dissolving formulations for immediate release and enhanced dissolution rate of active pharmaceutical ingredients
1) Dr.R. Santhosh Kumar
2) A.Suresh
Gitam Institute of Pharmacy, Gitam University, Visakhapatnam - Andhra Pradesh
An improved oxidant and solvent free one-step synthesis of 5-oxo chromeno pyridine derivatives
1) Asit Kumar Chakraborti
2) Naisargee Parikh
NIPER, Mohali
A phytoceutical product for skin care and process for the preparation thereof
1) Dhan Prakash
2) Charu Gupta
Amity University, Noida

Gene therapy drug approval granted to GSK

BBC reports that a new gene therapy base drug has been approved recently. Please see:

Regulators have given one of the world's largest drug companies approval to sell a new gene therapy. The treatment is for an illness called ADA-SCID which prevents babies from fighting off everyday infections. This is the first approval for a genetic therapy granted to a large multinational drug company, GSK. Commentators say the development marks the beginning of many more genetic medicines from so-called "Big Pharma". The condition is extremely rare and affects around two dozen babies each year.

Approval of the gene therapy paves the way for the development of treatments for more widespread illnesses such as thalassemia and sickle cell disease.

Hundreds of inherited disorders such as cystic fibrosis, muscular dystrophy and many types of blindness are caused by faulty genes.

The aim of gene therapies is to cure the disease by introducing healthy copies of the gene into the patient. And the big advantage of the treatment is that it only needs to be given once and it offers a potentially permanent cure. The idea first emerged with much hype 30 years ago. At the time, large drug companies such as Novartis and Roche were at the forefront of the technology.  Advocates of gene therapy said it would cure everything but, for 20 years, it cured nothing. The practicalities of introducing the right gene in the right cells and getting them to stick proved more difficult than first thought. There were huge setbacks for the technology in the early days.

In 1999, an 18-year-old man Jesse Gelsinger died in a clinical trial of a gene therapy to treat a liver disease. The virus used to transfer the gene into his cells triggered his immune system into overdrive which led to multiple organ failure and brain death.

Three years later, children being treated in Paris for a problem with their immune system developed leukaemia because the healthy gene was inserted too close to a cancer-causing gene which consequently became active.

The setbacks saw large drug companies withdraw from research in the field.

Small biotechnology companies and publicly funded research groups persevered and, in time, many     of the early difficulties were overcome.

As well as today's approval of GSK's treatment, which the company calls Strimvelis, in 2012 regulators gave the green light to a gene therapy called Glybera for a pancreatic disorder and another last year called T-Vec for skin cancer.
According to Prof Alan Boyd, who is president of the Faculty of Pharmaceutical Medicine and a pioneer in the development of gene therapy, more approvals are likely to be given in the next few years.

"Most of the hard work has been done by small companies. But as some of these products have come closer to market, Big Pharma has come back in," he says.

Significant step:
GSK's Strimvelis marks a starting point for the company to develop its gene therapies. It has research programmes under way for three relatively rare diseases and a programme and another collaboration to use gene therapy to treat cancers. One of the issues for Big Pharma is how can it make money out of gene therapy. If one treatment cures its customers then is the industry not in danger of putting itself out of business? GSK's position and those of other drug companies is that it can't afford not to become involved in gene therapy. If the vision to treat people with one-off treatments that last a long time becomes a reality, any part of the industry that chooses to ignore gene therapy will be in an awful lot of trouble. So the time is now right for large drug companies companies to become involved in gene therapy again. The question for Big Pharma the how much to charge for a single life-long cure?

Accessible to patients:
GSK has not released details of how it will price its new treatment yet but its president of R&D, Patrick Vallance, says that the aim would be to make Strimvelis and any more gene therapies it develops as accessible as possible to as many patients as it can. "We are absolutely committed to getting the price right," he says. "It's obvious that you can't charge a price that is unaffordable." No doubt the pricing will work itself out in the long run and as more trials come through, the cost of gene therapy treatments will get less and less. 

Tuesday, 24 May 2016

Dr. Hemchandra Tipnis, doyen of pharma profession, passes away

Dr. Hemchandra P. Tipnis, retired principal of Bombay College of Pharmacy (BCP) and Central Executive Council Member of Indian Pharmaceutical Association (IPA) passed away on May 23, 2016 after a cardiac arrest.

Born on July 7, 1933, Dr. Tipnis completed his Masters and Doctorate from University of California School of Pharmacy and University of Nebraska respectively. He pioneered the initial bioavailability studies in human volunteers and his research papers formed the basis for amendments to Drugs & Cosmetics Act, with the ultimate inclusion of Schedule Y in the Act. Dr Tipnis was amongst the first to understand the importance of industry tie-ups in growth of academic institutes and sew-up partnerships between the pharma industry and BCP, a move that propelled BCP into the big league of pharmacy colleges not just in the country but internationally as well.

Dr. Tipnis was active in the professional activities of IPA and was elected president of Indian Pharmaceutical Congress (IPC), the top, annual national pharma congregation, in 2007. He was also the scientific convener of IPCs in 1988, 1989,1990 & 1991. His vision and acumen helped Indian pharma industry get attuned to the global regulatory requirements and opened the doors to Indian ANDA filings with the USFDA. A recipient of many prestigious awards conferred by the pharma fraternity and IPA, Dr. Tipnis in his career guided 35 Doctorate and 100 Masters students; students who today literally are the ‘Who’s Who’ of the pharma profession globally.
Dr. Tipnis leaves behind a seemingly space in the pharma profession and more particularly pharma education sphere which cannot be filled. Indian Pharmaceutical Association, Bombay College of Pharmacy and the fraternity join hands in condoling the sad demise of this doyen of pharma profession.

Friday, 20 May 2016

By 2050, drug-resistant infections will kill 10m|yr

Antibiotics May Cease To Work Due To Overuse; Performing Caesarean, Chemo Could Become Dangerous

Urgent action is needed to control the use of antibiotics before they cease to work, leaving a number of major conditions untreatable and causing “terrible human and economic cost“, a major study has warned. Resistance to antibiotics is growing at such an alarming rate that they risk losing effectiveness entirely, meaning medical procedures such as caesarean sections, joint replacements and chemotherapy could soon become too dangerous to perform. Unless urgent action is taken, drug-resistant infections will kill 10 million people a year by 2050, the report's authors warn.

Drug-resistant infections are thought to be growing due to over-use of medicine such as antibiotics and antifungus treatments to treat minor conditions like the common cold. With over-use, resistance to the drugs builds up meaning some conditions become incurable and so-called `superbugs' such as MRSA develop.

Research has also suggested that antibiotic use in pig farming is common as poor living conditions mean such treatment is necessary to prevent infections spreading between livestock and that this passes down to humans thro ugh pork consumption, increasing resistance levels further. In the UK, 45% of all antibiotics are given to livestock.

The report is the result of a two-year review of the use of antibiotics undertaken by economist and former Goldman Sachs asset management chairman Lord Jim O'Neill. The review was commissioned amid growing concerns about the use of the medicines in the UK.

It calls for urgent action to halt the growing use of antibiotics: “to avoid the terrible human and economic costs of resistance that the world would otherwise face.” O'Neill calls for an awareness campaign on the harms of antibiotic use and restrictions on use of some critical antibiotics and a tax on the drugs to be introduced for livestock use.

The report estimates that without action now, the cost of the antibiotic failure will be $100 trillion before 2050.

O'Neill said of the findings: “My review not only makes it clear how big a threat antimicrobial resistance is to the world, with a potential 10 million people dying each year by 2050, but also now sets out a workable blueprint for bold, global action to tackle this challenge. The actions I'm setting out today are ambitious in their scope but this is a problem which it is well within our grasp to solve if we take action now... to avoid the terrible human and economic costs of resistance that the world will otherwise face.”

Chancellor of the Exchequer George Osborne welcomed the report saying: “O'Neill's review provides a stark warning that unless we take global action, antimicrobial resistance will become a greater threat to mankind than cancer currently is.


NPPA fixes price of 27 drug formulation packs

India Today reports that, drug price regulator NPPA has fixed the ceiling price of 27 drug formulation packs, including those used for the treatment of bacterial infections, diabetes, epilepsy among others.

Besides, the drug price regulator has also fixed the retail price of four formulations.

"NPPA has fixed/revised ceiling prices of 27 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and retail price of four formulations under DPCO, 2013," the National Pharmaceutical Pricing Authority (NPPA) said in a statement.

Earlier this month, the NPPA had fixed ceiling price of 54 drug formulations used for treatment of cancer, diabetes rheumatoid arthritis, bacterial infections and hypertension.

At present, the government fixes the prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment, having sales of more than 1 per cent.

Besides, the government regulates the prices of all other medicines and companies are allowed to hike prices of such drugs by up to 10 per cent in a year.

The government had notified DPCO, 2013, which covers 680 formulations, with effect from May 15, 2014, replacing the 1995 order that regulated prices of only 74 bulk drugs.

Set up in 1997, the NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of the Drugs (Prices Control) Order and monitoring of prices of controlled and decontrolled drugs.

For the details of the drugs, please visit:

Tattoo: No regulation on tattoo inks_From PharmaSastra

This post is from our cousin-blog PharmaSastra in Nepal. A really passionate, young, vibrant team is working on the blog for Nepalese community and pharma industry. 

Please visit:

These days in many parts of the world, people are tattooing their body with various inks. Its has been seen that even in the major cities of Nepal, this culture is increasing surprisingly. The main question here arise is "Is tattoo safe for our body?"

As the tattoo is the way of imprinting the pigments below our dermal layer. As the ink is exposed to our body, are we conscious about it? Is the concerned body really concerned about our health?

What the TATTOO ink contains?
As per the FDA is analyzing tattoo inks and pigments for contaminants, heavy metals, degradants, potentially toxic chemicals—including pH stabilizers, microbicides and coating agents—and other materials that are not intended to be placed into the body.  Its has been reported in many scientific articles that the tattoo ink contain everything from pigments used in printer toner to pigments used in car paint.

What might a tattoo ink may cause?
It may cause mild rash—redness or bumps—in the area of your tattoo, and you could develop a fever. Serious infections can require months of treatment with a variety of antibiotics. More virulent or aggressive infections may be associated with high fever, shaking, chills, and sweats. If these symptoms arise, you may need antibiotics, hospitalization and/or surgery.

Even after the high risk of the tattoo, the regulated bodies of Nepal is silent. This should be alarm notice to everyone who really cares about their health.

Thursday, 19 May 2016

Global antibiotics 'revolution' needed


A global revolution in the use of antimicrobials is needed, according to a government backed report.
Lord Jim O'Neill, who led the Review on Antimicrobial Resistance, said a campaign was needed to stop people treating antibiotics like sweets.

It is the first recommendation in the global plan for preventing medicine "being cast back into the dark ages".

The report has received a mixed response with some concerned that it does not go far enough.

Superbugs, resistant to antimicrobials, are estimated to account for 700,000 deaths each year. But modeling up to the year 2050, by Rand Europe and auditors KPMG, suggests 10 million people could die each year - equivalent to one every three seconds.

The report brings together eight previous interim reports that recommended:
§  An urgent and massive global awareness campaign as most people are ignorant of the risks
§  Establishing a $2bn ($1.4bn) Global Innovation Fund for early stage research
§  Improved access to clean water, sanitation and cleaner hospitals to prevent infections spreading
§  Reduce the unnecessary vast antibiotic use in agriculture including a ban on those "highly critical" to human health
§  Improved surveillance of the spread of drug resistance
§  Paying companies $1bn (£0.7bn) for every new antibiotic discovered
§  Financial incentives to develop new tests to prevent antibiotics being given when they will not work
§  Promoting the use of vaccines and alternatives to drugs

The review said the economic case for action "was clear" and could be paid for using a small cut of the current health budgets of countries or through extra taxes on pharmaceutical companies not investing in antibiotic research.

Lord Jim O'Neill, the economist who led the global review, said: "We need to inform in different ways, all over the world, why it's crucial we stop treating our antibiotics like sweets.

"If we don't solve the problem we are heading to the dark ages, we will have a lot of people dying. "We have made some pretty challenging recommendations which require everybody to get out of the comfort zone, because if we don't then we aren't going to be able to solve this problem."

Eight years of hell:
It is hoped the measures will prevent more people going through experiences like Emily Morris from Milton Keynes. She has regular urinary tract infections that do not respond to some antibiotics and could cause kidney damage or even death.

She says: "With every sting and every pain, my heart sinks at the thought of how many antibiotics I have left to use this time. "I've had the struggle of living with a resistance to antibiotics for nearly eight years of my life...there is a clear need for new antibiotics."

Pharma challenge:
Exactly how to encourage the drugs industry to make new antibiotics has been a long running problem - there has not been a new class of antibiotics discovered since the 1980s.

A new antibiotic would be kept on the shelf for use in emergencies so a company could never make back its huge research and development costs.

John Rex, from the antibiotics unit at AstraZeneca, said a new way of paying for drugs, as proposed in the report, was needed.

He argued: "Such models should recognise antibiotics as the healthcare equivalent of the fire extinguisher - they must be available on the wall at all times and have value even when used only infrequently."

Not enough:
But Dr Grania Brigden, from the charity Médecins Sans Frontières, said: "This report is an important first step in addressing this broad market failure, it does not go far enough."

MSF said infections resistant to drugs were a threat to their work around the world from the war-wounded in Jordan to newborns in Niger.

Dr Brigden added: "The O'Neill report proposes considerable new funding to overcome the failures of pharmaceutical research and development, but the proposals do not necessarily ensure access to either existing tools or emerging new products.

"Instead, in some cases, the report's solution is simply to subsidise higher prices rather than trying to overcome them."